Table 2. Characteristics and management of NADMs in PLWHH.
| Characteristics of NADMs | All patients n = 35 |
|
|---|---|---|
| Cancer type | ||
| Liver cancer | 15 (43%) | |
| Colon cancer | 5 (14%) | |
| Malignant lymphoma | 3 (9%) | |
| Papillary thyroid cancer | 2 (6%) | |
| Tongue cancer | 2 (6%) | |
| Neuroblastoma | 1 | |
| Malignant myeloma | 1 | |
| Prostate cancer | 1 | |
| Stomach cancer | 1 | |
| Renal cell carcinoma | 1 | |
| Gall bladder cancer | 1 | |
| Buccal mucosa cancer | 1 | |
| Pancreatic cancer | 1 | |
| Trigger of diagnosis | ||
| Health screening | 22 (63%) | |
| Presentation of symptoms | 8 (23%) | malignant lymphomas (n = 2), colon cancer (n = 2), tongue cancer (n = 1), buccal mucosal cancer (n = 1), neuroblastoma (n = 1), and multiple myeloma (n = 1) |
| Examination during regular visits | sit (14%) | |
| Metastasis at diagnosis | 10/34 (29%) | liver cancer (n = 5), malignant lymphomas (n = 2), buccal mucosal cancer (n = 1), neuroblastoma (n = 1), and multiple myeloma (n = 1) |
| Treatment | ||
| Only surgery | 15 (43%) | |
| Chemotherapy + radiation | 7 (20%) | |
| Only radiation | 4 (11%) | |
| Only chemotherapy | 3 (9%) | |
| Surgery + chemotherapy | 3 (9%) | |
| Surgery + chemotherapy + radiation | 2 (6%) | |
| Surgery + radiation | 1 | |
| Length of treatment | ||
| < 1 week | 11 (31%) | |
| 1 week to 6 months | 6 (17%) | |
| 6 months to 1 year | 8 (23%) | |
| 1-5 years | 8 (23%) | |
| > 5 years | 2 (6%) | |
| Outcome | ||
| Complete remission | 23/34 (68%) | |
| Partial remission | 3/34 (9%) | |
| Death due to malignancy | 6/34 (18%) | liver cancer (n=5), neuroblastoma (n = 1) |
| Death due to other causes | 1 | |
| Under treatment | 1 |
Abbreviations: AIDS, acquired immunodeficiency syndrome; HIV, human immunodeficiency virus; NADM, non-acquired immunodeficiency syndrome-defining malignancy; PLWHH, people living with haemophilia and the human immunodeficiency virus.